Formulations and Technologies in Growth Hormone Delivery

Mohammed, Gubran Khalil; Obaidat, Rana; Assaf, Shereen M.; Khanfar, Mai; Al-Taani, Bashar

doi:10.22159/ijpps.2017.v9i7.18079

Cited by 5 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of this, it is a treatment with very low adherence and, therefore, it needs improvement. Among the new strategies developed, the most promising are those that permit reaching long-lasting formulations with noninvasive administration routes [95,96]. With regard to the remaining growth factors, mostly cytokines and steroid hormones, it is typical to have compounds with very little aqueous solubility.…”

Section: Growth Factorsmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules

Castillo

Lozano

2020

Pharmaceutics

View full text Add to dashboard Cite

The enormous versatility of mesoporous silica nanoparticles permits the creation of a large number of nanotherapeutic systems for the treatment of cancer and many other pathologies. In addition to the controlled release of small drugs, these materials allow a broad number of molecules of a very different nature and sizes. In this review, we focus on biogenic species with therapeutic abilities (proteins, peptides, nucleic acids, and glycans), as well as how nanotechnology, in particular silica-based materials, can help in establishing new and more efficient routes for their administration. Indeed, since the applicability of those combinations of mesoporous silica with bio(macro)molecules goes beyond cancer treatment, we address a classification based on the type of therapeutic action. Likewise, as illustrative content, we highlight the most typical issues and problems found in the preparation of those hybrid nanotherapeutic materials.

show abstract

Section: Growth Factorsmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules

Castillo

Lozano

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Already in 1974, the pharmaceutical company Sandoz GmbH, Germany, initiated a project to obtain long-acting synthetic analogues with a higher activity vs native somatostatin. Later, SSAs were created, which proved to be more resistant to enzymatic decomposition and possessed improved pharmacokinetic and therapeutic characteristics [14,15].…”

Section: Introductionmentioning

confidence: 99%

Somatostatin Analogues for the Treatment of Neuroendocrine Tumours. Dosage Forms and Routes of Administration (Review)

Shprakh¹

2020

Int J App Pharm

View full text Add to dashboard Cite

This review summarises information on drug products Somatostatin Analogues (SSAs), which are included in the algorithm of Neuroendocrine Tumors (NET) treatment. SSAs are the current standard for safe and effective management of NET symptoms and control of tumours growth and are administered in a range of dosage forms for parenteral administration, such as intramuscular, subcutaneous and implant. A search criterion was the therapy of NET with medicines from a group of SSAs. Literature survey has been done in a range of years 1990-2018 to make the review updated and comprehensive and to show the development of SSAs new pharmaceutical dosage forms to improve patient quality of life and side effects decrease. The sources were world-recognized journals. Keywords used as filters were NET, SSAs, octreotide, lanreotide, pasireotide, Somatostatin Receptors (SSTR), dosage form. The current review is created with an intended to focus on the advantage of SSAs modern dosage forms. Literature survey revealed that many studies were carried out to SSAs encapsulation into microspheres that changes the drug bioavailability and allows reducing the number of administration. Also, SSAs delivery systems in particular devices such as auto-injector have been created to control the continuous concentration of the drug and to provide safety guarantee. Besides, studies have been carried out to prepare SSAs formulations for oral administration to improve the quality of life of the NET patients. In this review, SSAs pharmaceutical dosage forms with improved pharmacokinetic and therapeutic characteristics and routes of administration are analyzed.

show abstract

“…Usually, parenteral way of administration is used for peptide drug administration because of their enzymatic instability [6,7]. But cyphetrylin is insoluble in water, and it is metabolically stable in the gastric fluid because of reactive groups blocking.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Somatostatin Analogue Tablets

Shprakh

Орлова²,

Оборотова³

et al. 2019

Int J App Pharm

View full text Add to dashboard Cite

Objective: This study was undertaken with the aim of the formulation and evaluation of hypothalamic hormone somatostatin analogue tablets, which are intended for neuroendocrine tumours treatment. Methods: Tablets were prepared by using the wet granulation method and evaluated for weight variation, resistance to crushing, friability, disintegration time, content and content uniformity. Stability tests have been performed. Results: Characteristics of somatostatin analogue cyphetrylin powder have been investigated, and the wet granulation method has been chosen to prepare tablets. Technical pharmaceutical properties of formulations of different compositions and obtained tablets were estimated and the best formulation CF11 has been established with appropriate characteristics: disintegration time less than 15 min, resistance to crushing more than 30 kg·m·s−2, weight variation ˂7.5 %, active substance content closed to the nominal quantity and consistent cyphetrylin distribution in the batch. Performed examinations showed cyphetrylin tablets stability in the long-term study. Conclusion: Because of somatostatin analogue cyphetrylin powder properties tablets were prepared by the wet granulation method with starch, lactose, povidone, talc, microcrystalline cellulose, calcium stearate and magnesium stearate as excipients. The best formulation including povidone has characteristics corresponding to requirements of European Pharmacopoeia (PhEur) and State Pharmacopoeia of the Russian Federation (PhRu). Examination of cyphetrylin tablets showed its quality and stability within the time of observation–12 mo.

show abstract

Formulations and Technologies in Growth Hormone Delivery

Cited by 5 publications

References 76 publications

Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules

Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules

Somatostatin Analogues for the Treatment of Neuroendocrine Tumours. Dosage Forms and Routes of Administration (Review)

Formulation and Evaluation of Somatostatin Analogue Tablets

Contact Info

Product

Resources

About